Assoc. Prof. of Urology / Translational Research in Uro-Oncology, Lasers & Pediatric Urology / Sports Climbing and Bouldering
Würzburg, Deutschland
Joined March 2019
- Tweets272
- Following265
- Followers308
- Likes971
chariskalogirou retweeted
Apply now, spread the word: three (3) fully funded Helmholtz research groups (assistant prof level) with attractive packages. Topics: RNA-based medicine, microbial RNA, and RNA-based infection research incl. RNA technologies. Great environment for young people. Come and join us.
chariskalogirou retweeted
Congratulations to Pailin Pongratanakul for winning the 1st Hans Flohr award with our ‚growing teratoma‘-study at this year’s C. E. Alken conference in Frankfurt a. M…. 🍾🏆💪🏻
@UniklinikDUS
@MedHHU
@HHU_de
@DGUrologie
chariskalogirou retweeted
If you ever wondered how advanced urothelial carcinoma evolves during metastatic spread
👉 Read our review about #bladder cancer #metastsis and #evolution in @NatRevUrol ! Thanks for highlighting @brookmans76 @niklas_kluemper @imedverse @urotoday @OncoAlert
Are pre-treatment #biopsies the way to go in mUC?
☑️Response prediction to immunotherapy, anti-NECTIN4 ADC enfortumab vedotin, FGFR inhibitor erdafitinib
☑️Identification of druggable alterations and treatment selection
@Markuseckstein3 @niklas_kluemper @oncodaily #BladderCancer
chariskalogirou retweeted
Nice summary of where we are with the DRE. Academic urologists--do you still ask your team to include with their H&P?
Is Era of the Digital Rectal Examination (DRE) for Prostate ... : JU Open Plus journals.lww.com/juop/fullte…
chariskalogirou retweeted
1/5 Big news from Aguilar Lab! Check out our first preprint! We’ve developed a new prostate organoid model to crack the mystery of E. coli prostatitis, a common, tough-to-treat infection in men. Our model reveals how these bacteria get in and thrive. #UPEC #Organoids #UTI
Prostate-specific membrane receptor PPAP facilitates E. coli invasion of luminal prostate cells via FimH binding biorxiv.org/cgi/content/shor… #biorxiv_molbio
chariskalogirou retweeted
Special thanks to the Single Cell Center Würzburg @SCC_Wurzburg, @AE_Saliba, and @chariskalogirou for their support!
chariskalogirou retweeted
We had some intense brainstorming and active discussions on research topics and problems in #prostatecancer at Apollo meeting by @IpsenGroup👍
It was priceless to learn the personal stories of our mentors and to get an expert advice on our ongoing projects. Thank you!🙌
chariskalogirou retweeted
After several years immersed in clinic and teaching, the Apollo project has been an incredible encounter to start improving my research skills. It is an honor to have met my mentor @joniau and the rest of the faculty. Long live the Apollo project and thanks to @IpsenGroup – at Greece
chariskalogirou retweeted
Ready for a very interesting day in Athens on how to progress with prostate cancer research! A big thanks to the Apollo-program!
chariskalogirou retweeted
Winning the Maximilian Nitze Price of the @DGUrologie #DGU24 is the most important scientific award in academic urology and urooncology in Germany.
@niklas_kluemper made it 🎉🍾!!! Well deserved for your hard and dedicated work for advancing medical care for urlthelial cancer patients !
@OncoAlert @urotoday @Uroweb @imedverse @amerseburger @niklas_kluemper
chariskalogirou retweeted
Honored to share the 🇺🇾🇦🇷experience with #PaclitaxelDextranCoatedBalloon for Post Operative Ureteral Strictures during #WCET24 🇰🇷 #SEOUL
BS1:15 📁
#JavierZeballos @SauUrologia @ResidentesCAU @ResidentesCAU @Endo_Society @luisrico89 @AlexRuebben @AmerUrological @Uroweb @UrowebESU
chariskalogirou retweeted
⚠️⚠️⚠️Publication alert!⚠️⚠️⚠️
nature.com/articles/s41556-0…
Congratulations #BrabletzLab and @KoeberleLab for this amazing study.
Happy to have played a tiny role
#ferroptosis #lipidmetabolism #cancerplasticity
chariskalogirou retweeted
Great to have @tompowles1 at #UroTrials in Düsseldorf. Prediction: 80% less cystectomies in the next five years given recent advances in the field. So rCx only in case of local complications/bleeding in the future? @amerseburger @JimCatto @daviesbj @uretericbud
chariskalogirou retweeted
📌 Prostate cancer
⏩ Phase Ib trial
-Tarlatamab Tarlatamab showed manageable safety profile in Neuroendocrine #Prostate #Cancer, showing antitumor activity on DLL3 expression.
#ASCO24 @OncoAlert
chariskalogirou retweeted
Exciting advances in prostate cancer treatment at #ASCO24!
⚪️ JNJ-6420, a novel anti-hK2 Ab-based targeted #radiotherapy, shows promising results in heavily pretreated mCRPC patients.
⚪️ Despite notable adverse events, profound and durable responses were observed at ≥150 μCi doses.
@ASCO @OncoAlert
Bloodless R0 en-bloc TURBT for solitary pT2a #bladdercancer with @quanta_system #virtualbasket mode. Smooth resection surface, specimen retrieval with bag, 30min OR time. Are there any arguments left for classic TURBT? #urosome #urology #lasers #endoscopy
chariskalogirou retweeted
⭐️ RAPID ORALS RENAL ⭐️
“Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).”
Dr Martin Zarba @DrDanielHeng
IMDC FAV (n = 611)
✅ Nivo/Ipi: ORR (35%), 2yr OS 86.4%
✅ IO/TKI: ORR (51.4%), 2yr OS 84.1%
✅ TKI: ORR (37.9%), 2yr OS 81.1%
IMDC VERY FAV (n= 165)
(Dx to systemic therapy ≥3yr,
KPS > 90, and no brain, liver, or bone metastasis)
✅ Nivo/Ipi: ORR (23.5%), 2yr OS 71.3%
✅ IO/TKI: ORR (58.1%), 2yr OS 87.2%
✅ TKI: ORR (55%), 2yr OS 92.1%
chariskalogirou retweeted
Dr. Jae-Lyun Lee PhII mFOLFIRINOX for #1L adv #urachalcancer
n=21
ORR 61.9% (2 CRs)
Median PFS 9.3 mos
Median OS 26.4 mos
No febrile neutropenia or G4 events w/prophylactic GCSF on protocol #ASCO24
@OncoAlert
chariskalogirou retweeted
IMDC analysis of very favorable risk mRCC (0 risk factors, time from diagnosis to systemic therapy ≥3 yrs, no brain/liver/bone mets, KPS ≥90%)
🔹IO+VEGF & VEGF mono associated with best OS outcomes, compared to ipi/nivo (2-yr: ~90% vs 71%)
🔹ORR: 55-58% with VEGF +/- IO vs ipi/nivo (23.5%)
🚩Importance of VEGF inh in this subgroup
@urotoday #ASCO24
chariskalogirou retweeted
🏆 State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers 🏆
“Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?”
@YuWeiChenMD
1. VEGFR TKI proven role in IO refractory setting
2. Role of IO after IO/IO or IO/TKI remains uncertain: awaiting results of TiNivo2
3. Belzutfan approved in refractory ccRCC- how to select patients in clinic? Will we find a biomarker?
4: Post Adjuvant Pembr?
@TalalZarif1 Poster Presentation 6/2/24
@ASCO @OncoAlert #ASCO24
